Home › Encyclopedia › Thymopentin: Research Status, Identity, and Trial Data
Research / Unapproved

Thymopentin: Research Status, Identity, and Trial Data

Molecular formulaC30H49N9O9
Molecular weight679.8 g/mol
Registered trials12
PubChem CID451417

Regulatory status

Thymopentin is classified as an unapproved research compound. No FDA label, approved indication, or approved brand name exists for it in the data reviewed.

What thymopentin is

Thymopentin is a synthetic peptide with the molecular formula C30H49N9O9 and a molecular weight of approximately 679.8. It is listed in PubChem under CID 451417. No approved drug label describes its mechanism of action or intended use.

Trial footprint

Thymopentin has 12 registered clinical trials. Several of the sampled studies examined thymopentin in people with HIV-1 infection. One such trial was a double blind study of thymopentin's effects on patients with HIV-1 infection, which reached completed status. A related double blind trial looked at thymopentin's effects on HIV-1 infectivity of blood mononuclear cells and semen in HIV infected patients, also completed. Another sampled trial studied Timunox, a thymopentin product, in HIV-infected patients who were also receiving other anti-HIV drugs; that trial reached completed status as well. These records describe trial registration and status only, not outcomes or effectiveness.

FAQ

Is thymopentin FDA approved?
No. Thymopentin does not have an approved FDA label or indication based on the data reviewed. It is classified as an unapproved research compound.
What is thymopentin chemically?
Thymopentin is a synthetic peptide with the molecular formula C30H49N9O9 and a molecular weight of about 679.8. It is catalogued in PubChem under CID 451417.
Has thymopentin been studied in clinical trials?
Yes. There are 12 registered clinical trials involving thymopentin, including several double blind studies conducted in patients with HIV-1 infection. These trials reflect registration and completion status, not proof of effectiveness.
What conditions have thymopentin trials focused on?
Sampled trials have focused on HIV-1 infection, including studies of thymopentin's effects on infectivity of blood mononuclear cells and semen, and a study of a thymopentin product called Timunox used alongside other anti-HIV drugs.
Does thymopentin have known side effects?
No adverse event report data was available for thymopentin in the sources reviewed, so no side effect pattern can be summarized here.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem ClinicalTrials.gov

Updated 2026-11-07